Indans

• 

  Subject Areas on Research

  • A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. 
  • A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. 
  • Cholinergic therapy for Down's syndrome. 
  • Comparative cardiovascular safety of dementia medications: a cross-national study. 
  • Defining meaningful change in Alzheimer's disease trials: the donepezil experience. 
  • Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial. 
  • Donepezil for Down's syndrome. 
  • Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial. 
  • Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial. 
  • Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17. 
  • Donepezil treatment of older adults with cognitive impairment and depression (DOTCODE study): clinical rationale and design. 
  • Donepezil use in Down syndrome. 
  • Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats. 
  • Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging. 
  • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. 
  • Emerging pharmacotherapy for cancer patients with cognitive dysfunction. 
  • Endothelin antagonism and contrast nephropathy. 
  • Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. 
  • Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. 
  • Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series. 
  • Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder. 
  • Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. 
  • Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. 
  • Synthesis, dopaminergic profile, and molecular dynamics calculations of N-aralkyl substituted 2-aminoindans. 
  • The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. 
  • Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized controlled trial. 
  • Treating cognitive deficits in multiple sclerosis: are we there yet? 
  • Update on Alzheimer's disease. Promising advances in detection and treatment. 
  • When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis. 
  • [Novel central dopaminergic agents derived from atypical di-substituted 2-aminoindane-4, 7. Synthesis and central pharmacological profile]. 
  • mGluR modulation of post-traumatic neuronal death: role of NMDA receptors. 
• 

  Keywords of People

  • Charles, Hal Cecil, Adjunct Associate Professor in the Department of Radiology, Radiology